IART Integra LifeSciences Holdings Corporation

Integra LifeSciences to Present at 41st Annual J.P. Morgan Healthcare Conference

Integra LifeSciences to Present at 41st Annual J.P. Morgan Healthcare Conference

PRINCETON, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, announced today that Jan De Witte, president and chief executive officer will present at the 41st Annual J.P. Morgan Healthcare conference on January 11, 2023 at 7:30pm ET.

A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at .

About Integra LifeSciences

Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, BioD™, CerebroFlo®, CereLink® Certas® Plus, Codman®, CUSA®, Cytal®, DuraGen®, DuraSeal®, Gentrix®, ICP Express®, Integra®, Licox®, MAYFIELD®, MediHoney®, MicroFrance®, MicroMatrix®, NeuraGen®, PriMatrix®, SurgiMend®, TCC-EZ® and VersaTru®. For the latest news and information about Integra and its products, please visit .

CONTACTS:

Investor Relations:

Chris Ward (609) 772-7736

Media:

Laurene Isip (609) 208-8121



EN
21/12/2022

Underlying

IARTIntegra LifeSciences Holdings Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Integra LifeSciences Holdings Corporation

 PRESS RELEASE
Free
IART Integra LifeSci...

Integra LifeSciences Reports Second Quarter 2025 Financial Results

Integra LifeSciences Reports Second Quarter 2025 Financial Results PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2025. Second Quarter 2025 Highlights Second quarter revenues exceeded guidance; adjusted earnings per diluted share (EPS) at the top end of the rangeSecond quarter revenues of $415.6 million decreased (0.6)% on a reported basis and (1.4)% on an organic basis compared to the prior year.Second quarter GAAP earnings per diluted share of $...

July 31, 2025 1 EN
 PRESS RELEASE
Free
IART Integra LifeSci...

Integra LifeSciences to Host Second Quarter 2025 Financial Results Con...

Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025 PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: IART), a leading global medical technology company, will release second quarter 2025 financial results on Thursday, July 31, 2025, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the call, register  to receive dial-in...

July 14, 2025 1 EN
 PRESS RELEASE
Free
IART Integra LifeSci...

Integra LifeSciences Announces First Patient Enrolled in Acclarent AER...

Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, is proud to announce enrollment of the first patient in the Acclarent AERA Pediatric Registry, a prospective, multi-center observational registry evaluating the real-world use of the in children. This inaugural enrollment marks the focused effort to measure the ongoing, real-world clinical performance of AERA in pediatric patients with obstructive Eustachian tube dysfunction (ETD). Dr....

July 2, 2025 1 EN
 PRESS RELEASE
Free
IART Integra LifeSci...

Integra LifeSciences Reports First Quarter 2025 Financial Results

Integra LifeSciences Reports First Quarter 2025 Financial Results PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55...

May 5, 2025 1 EN
 PRESS RELEASE
Free
IART Integra LifeSci...

Integra LifeSciences to Host First Quarter 2025 Financial Results Conf...

Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025 PRINCETON, N.J., April 18, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: IART), a leading global medical technology company, will release first quarter 2025 financial results on Monday, May 5, 2025, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the call, register  to receive dial-in detail...

April 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch